The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-10-19

AUTHORS

Ahmed H. Seddik, Nima Melzer, Foteini Tsotra, Dennis A. Ostwald

ABSTRACT

ObjectivesModerate to severe plaque psoriasis is a chronic inflammatory disease. In Germany, guidelines recommend fumaric acid esters (FAEs) as first-line systemic treatment. Despite treatment with FAEs, disease burden remains high in Germany. Secukinumab, a fully human monoclonal antibody, has demonstrated greater efficacy and safety than FAEs in the PRIME trial. The aim of the current study, hence, is to quantify the potential societal economic impact of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis in Germany.MethodsWe employed a semi-Markov model to capture health gains at an individual level and a dynamic population model to extrapolate the findings in the population of interest. We quantified the health outcomes in two scenarios: (i) patients receiving secukinumab and (ii) patients receiving FAEs. Using estimates on change in work productivity and societal economic parameters, we translated the health outcomes into paid and unpaid economic gains. We used gross value added (GVA) to value these gains and calculated the macroeconomic indirect and induced value-chain effects.ResultsOur calculations show that patients treated with secukinumab spend on average 94% of their time in Psoriasis Area and Severity Index (PASI) ≥ 75 state compared with 80% for patients in the FAEs scenario. When assuming that FAEs are the sole comparator to secukinumab, this difference could lead to 4.3 million active hours gained until 2030. These gained hours translate to a total societal economic impact of €308 million till 2030 for the whole patient population in GVA terms.ConclusionThis study demonstrated that using secukinumab instead of FAEs in moderate to severe plaque psoriasis could lead to substantial macroeconomic GVA gains. More... »

PAGES

1-11

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41669-021-00305-3

DOI

http://dx.doi.org/10.1007/s41669-021-00305-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1142003256

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34668167


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Daiichi-Sankyo Europe GmbH, Munich, Germany", 
          "id": "http://www.grid.ac/institutes/grid.488273.2", 
          "name": [
            "Daiichi-Sankyo Europe GmbH, Munich, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seddik", 
        "givenName": "Ahmed H.", 
        "id": "sg:person.012645115554.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012645115554.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, Nuremberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, Nuremberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Melzer", 
        "givenName": "Nima", 
        "id": "sg:person.01015567176.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015567176.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "WifOR Institute, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "WifOR Institute, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsotra", 
        "givenName": "Foteini", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "SIBE, Graduate School of the Faculty for Leadership and Management, Steinbeis University, Berlin, Germany", 
          "id": "http://www.grid.ac/institutes/grid.461823.a", 
          "name": [
            "WifOR Institute, Darmstadt, Germany", 
            "SIBE, Graduate School of the Faculty for Leadership and Management, Steinbeis University, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ostwald", 
        "givenName": "Dennis A.", 
        "id": "sg:person.010221655562.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010221655562.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12913-017-2278-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085209002", 
          "https://doi.org/10.1186/s12913-017-2278-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00403-016-1637-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001737915", 
          "https://doi.org/10.1007/s00403-016-1637-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-014-0053-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000406083", 
          "https://doi.org/10.1007/s13555-014-0053-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00281-019-00766-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122230536", 
          "https://doi.org/10.1007/s00281-019-00766-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-10-19", 
    "datePublishedReg": "2021-10-19", 
    "description": "ObjectivesModerate to severe plaque psoriasis is a chronic inflammatory disease. In Germany, guidelines recommend fumaric acid esters (FAEs) as first-line systemic treatment. Despite treatment with FAEs, disease burden remains high in Germany. Secukinumab, a fully human monoclonal antibody, has demonstrated greater efficacy and safety than FAEs in the PRIME trial. The aim of the current study, hence, is to quantify the potential societal economic impact of secukinumab in systemic treatment-na\u00efve patients with moderate to severe plaque psoriasis in Germany.MethodsWe employed a semi-Markov model to capture health gains at an individual level and a dynamic population model to extrapolate the findings in the population of interest. We quantified the health outcomes in two scenarios: (i) patients receiving secukinumab and (ii) patients receiving FAEs. Using estimates on change in work productivity and societal economic parameters, we translated the health outcomes into paid and unpaid economic gains. We used gross value added (GVA) to value these gains and calculated the macroeconomic indirect and induced value-chain effects.ResultsOur calculations show that patients treated with secukinumab spend on average 94% of their time in Psoriasis Area and Severity Index (PASI) \u2265\u00a075 state compared with 80% for patients in the FAEs scenario. When assuming that FAEs are the sole comparator to secukinumab, this difference could lead to 4.3 million active hours gained until 2030. These gained hours translate to a total societal economic impact of \u20ac308 million till 2030 for the whole patient population in GVA terms.ConclusionThis study demonstrated that using secukinumab instead of FAEs in moderate to severe plaque psoriasis could lead to substantial macroeconomic GVA gains.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41669-021-00305-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1284515", 
        "issn": [
          "2509-4262", 
          "2509-4254"
        ], 
        "name": "PharmacoEconomics - Open", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }
    ], 
    "keywords": [
      "severe plaque psoriasis", 
      "fumaric acid esters", 
      "plaque psoriasis", 
      "societal economic impact", 
      "health outcomes", 
      "systemic treatment-na\u00efve patients", 
      "first-line systemic treatment", 
      "treatment-na\u00efve patients", 
      "whole patient population", 
      "chronic inflammatory disease", 
      "human monoclonal antibody", 
      "ResultsOur calculations", 
      "systemic treatment", 
      "Psoriasis Area", 
      "line treatment", 
      "patient population", 
      "inflammatory diseases", 
      "disease burden", 
      "secukinumab", 
      "patients", 
      "psoriasis", 
      "greater efficacy", 
      "ConclusionThis study", 
      "health gains", 
      "monoclonal antibodies", 
      "work productivity", 
      "Severity Index", 
      "prime trials", 
      "treatment", 
      "population of interest", 
      "outcomes", 
      "current study", 
      "economic impact", 
      "population", 
      "MethodsWe", 
      "disease", 
      "trials", 
      "antibodies", 
      "efficacy", 
      "burden", 
      "individual level", 
      "study", 
      "active hours", 
      "hours", 
      "safety", 
      "guidelines", 
      "aim", 
      "findings", 
      "index", 
      "gain", 
      "impact", 
      "levels", 
      "differences", 
      "comparator", 
      "effect", 
      "dynamic population model", 
      "changes", 
      "acid esters", 
      "Germany", 
      "esters", 
      "time", 
      "translates", 
      "area", 
      "model", 
      "values", 
      "estimates", 
      "interest", 
      "parameters", 
      "state", 
      "population model", 
      "terms", 
      "semi-Markov model", 
      "scenarios", 
      "economic parameters", 
      "gross value", 
      "economic gains", 
      "productivity", 
      "calculations", 
      "simulations", 
      "ObjectivesModerate", 
      "potential societal economic impact", 
      "societal economic parameters", 
      "unpaid economic gains", 
      "induced value-chain effects", 
      "value-chain effects", 
      "FAEs scenario", 
      "sole comparator", 
      "hours translate", 
      "total societal economic impact", 
      "GVA terms", 
      "substantial macroeconomic GVA gains", 
      "macroeconomic GVA gains", 
      "GVA gains", 
      "An Open-Cohort Simulation", 
      "Open-Cohort Simulation"
    ], 
    "name": "The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation", 
    "pagination": "1-11", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1142003256"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41669-021-00305-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34668167"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41669-021-00305-3", 
      "https://app.dimensions.ai/details/publication/pub.1142003256"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T19:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_877.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41669-021-00305-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00305-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00305-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00305-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00305-3'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      22 PREDICATES      123 URIs      111 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41669-021-00305-3 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N774c9a7996314f1d8b8bcfba34f9ce21
4 schema:citation sg:pub.10.1007/s00281-019-00766-z
5 sg:pub.10.1007/s00403-016-1637-8
6 sg:pub.10.1007/s13555-014-0053-2
7 sg:pub.10.1186/s12913-017-2278-0
8 schema:datePublished 2021-10-19
9 schema:datePublishedReg 2021-10-19
10 schema:description ObjectivesModerate to severe plaque psoriasis is a chronic inflammatory disease. In Germany, guidelines recommend fumaric acid esters (FAEs) as first-line systemic treatment. Despite treatment with FAEs, disease burden remains high in Germany. Secukinumab, a fully human monoclonal antibody, has demonstrated greater efficacy and safety than FAEs in the PRIME trial. The aim of the current study, hence, is to quantify the potential societal economic impact of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis in Germany.MethodsWe employed a semi-Markov model to capture health gains at an individual level and a dynamic population model to extrapolate the findings in the population of interest. We quantified the health outcomes in two scenarios: (i) patients receiving secukinumab and (ii) patients receiving FAEs. Using estimates on change in work productivity and societal economic parameters, we translated the health outcomes into paid and unpaid economic gains. We used gross value added (GVA) to value these gains and calculated the macroeconomic indirect and induced value-chain effects.ResultsOur calculations show that patients treated with secukinumab spend on average 94% of their time in Psoriasis Area and Severity Index (PASI) ≥ 75 state compared with 80% for patients in the FAEs scenario. When assuming that FAEs are the sole comparator to secukinumab, this difference could lead to 4.3 million active hours gained until 2030. These gained hours translate to a total societal economic impact of €308 million till 2030 for the whole patient population in GVA terms.ConclusionThis study demonstrated that using secukinumab instead of FAEs in moderate to severe plaque psoriasis could lead to substantial macroeconomic GVA gains.
11 schema:genre article
12 schema:inLanguage en
13 schema:isAccessibleForFree true
14 schema:isPartOf sg:journal.1284515
15 schema:keywords An Open-Cohort Simulation
16 ConclusionThis study
17 FAEs scenario
18 GVA gains
19 GVA terms
20 Germany
21 MethodsWe
22 ObjectivesModerate
23 Open-Cohort Simulation
24 Psoriasis Area
25 ResultsOur calculations
26 Severity Index
27 acid esters
28 active hours
29 aim
30 antibodies
31 area
32 burden
33 calculations
34 changes
35 chronic inflammatory disease
36 comparator
37 current study
38 differences
39 disease
40 disease burden
41 dynamic population model
42 economic gains
43 economic impact
44 economic parameters
45 effect
46 efficacy
47 esters
48 estimates
49 findings
50 first-line systemic treatment
51 fumaric acid esters
52 gain
53 greater efficacy
54 gross value
55 guidelines
56 health gains
57 health outcomes
58 hours
59 hours translate
60 human monoclonal antibody
61 impact
62 index
63 individual level
64 induced value-chain effects
65 inflammatory diseases
66 interest
67 levels
68 line treatment
69 macroeconomic GVA gains
70 model
71 monoclonal antibodies
72 outcomes
73 parameters
74 patient population
75 patients
76 plaque psoriasis
77 population
78 population model
79 population of interest
80 potential societal economic impact
81 prime trials
82 productivity
83 psoriasis
84 safety
85 scenarios
86 secukinumab
87 semi-Markov model
88 severe plaque psoriasis
89 simulations
90 societal economic impact
91 societal economic parameters
92 sole comparator
93 state
94 study
95 substantial macroeconomic GVA gains
96 systemic treatment
97 systemic treatment-naïve patients
98 terms
99 time
100 total societal economic impact
101 translates
102 treatment
103 treatment-naïve patients
104 trials
105 unpaid economic gains
106 value-chain effects
107 values
108 whole patient population
109 work productivity
110 schema:name The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation
111 schema:pagination 1-11
112 schema:productId N0e6d7d6a8c1747319576a0feb3b3838f
113 N1ac5af45434049a88cc43ae8bcf196c1
114 N41bb74dd28a640039fe3ab95117a8253
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142003256
116 https://doi.org/10.1007/s41669-021-00305-3
117 schema:sdDatePublished 2022-01-01T19:00
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher Nd6f582325cab42fc9cc5c1c201e1bd4b
120 schema:url https://doi.org/10.1007/s41669-021-00305-3
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N047af6eba6444cb284413fe8822b0e80 rdf:first sg:person.010221655562.35
125 rdf:rest rdf:nil
126 N0e6d7d6a8c1747319576a0feb3b3838f schema:name dimensions_id
127 schema:value pub.1142003256
128 rdf:type schema:PropertyValue
129 N1ac5af45434049a88cc43ae8bcf196c1 schema:name pubmed_id
130 schema:value 34668167
131 rdf:type schema:PropertyValue
132 N41bb74dd28a640039fe3ab95117a8253 schema:name doi
133 schema:value 10.1007/s41669-021-00305-3
134 rdf:type schema:PropertyValue
135 N774c9a7996314f1d8b8bcfba34f9ce21 rdf:first sg:person.012645115554.88
136 rdf:rest N807892baab474e6db595beb403b96eda
137 N807892baab474e6db595beb403b96eda rdf:first sg:person.01015567176.10
138 rdf:rest Nc5e0d6ffa68f443a80e134a747be8285
139 Nc5e0d6ffa68f443a80e134a747be8285 rdf:first Nf37dca7218a74507b622f11cb8344c54
140 rdf:rest N047af6eba6444cb284413fe8822b0e80
141 Nd6f582325cab42fc9cc5c1c201e1bd4b schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 Nf37dca7218a74507b622f11cb8344c54 schema:affiliation grid-institutes:None
144 schema:familyName Tsotra
145 schema:givenName Foteini
146 rdf:type schema:Person
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
151 schema:name Clinical Sciences
152 rdf:type schema:DefinedTerm
153 sg:journal.1284515 schema:issn 2509-4254
154 2509-4262
155 schema:name PharmacoEconomics - Open
156 schema:publisher Springer Nature
157 rdf:type schema:Periodical
158 sg:person.01015567176.10 schema:affiliation grid-institutes:grid.467675.1
159 schema:familyName Melzer
160 schema:givenName Nima
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015567176.10
162 rdf:type schema:Person
163 sg:person.010221655562.35 schema:affiliation grid-institutes:grid.461823.a
164 schema:familyName Ostwald
165 schema:givenName Dennis A.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010221655562.35
167 rdf:type schema:Person
168 sg:person.012645115554.88 schema:affiliation grid-institutes:grid.488273.2
169 schema:familyName Seddik
170 schema:givenName Ahmed H.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012645115554.88
172 rdf:type schema:Person
173 sg:pub.10.1007/s00281-019-00766-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1122230536
174 https://doi.org/10.1007/s00281-019-00766-z
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s00403-016-1637-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001737915
177 https://doi.org/10.1007/s00403-016-1637-8
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s13555-014-0053-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000406083
180 https://doi.org/10.1007/s13555-014-0053-2
181 rdf:type schema:CreativeWork
182 sg:pub.10.1186/s12913-017-2278-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085209002
183 https://doi.org/10.1186/s12913-017-2278-0
184 rdf:type schema:CreativeWork
185 grid-institutes:None schema:alternateName WifOR Institute, Darmstadt, Germany
186 schema:name WifOR Institute, Darmstadt, Germany
187 rdf:type schema:Organization
188 grid-institutes:grid.461823.a schema:alternateName SIBE, Graduate School of the Faculty for Leadership and Management, Steinbeis University, Berlin, Germany
189 schema:name SIBE, Graduate School of the Faculty for Leadership and Management, Steinbeis University, Berlin, Germany
190 WifOR Institute, Darmstadt, Germany
191 rdf:type schema:Organization
192 grid-institutes:grid.467675.1 schema:alternateName Novartis Pharma GmbH, Nuremberg, Germany
193 schema:name Novartis Pharma GmbH, Nuremberg, Germany
194 rdf:type schema:Organization
195 grid-institutes:grid.488273.2 schema:alternateName Daiichi-Sankyo Europe GmbH, Munich, Germany
196 schema:name Daiichi-Sankyo Europe GmbH, Munich, Germany
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...